| Size | Price | Stock | Qty |
|---|---|---|---|
| 500g |
|
||
| Other Sizes |
| Targets |
(R)-2-((Methoxycarbonyl)amino)-2-phenylacetic acid does not have a defined biological target as a building block. The methoxycarbonyl (MOC) group is a carbamate that can interact with serine hydrolases (e.g., fatty acid amide hydrolase, FAAH) by reacting with the active site serine to form a stable carbamoylated enzyme, leading to inhibition. However, this compound itself has not been reported as an FAAH inhibitor. When incorporated into larger molecules, the D-phenylglycine residue may target penicillin-binding proteins (PBPs) in bacteria (as in ampicillin and amoxicillin, which contain D-phenylglycine), or the glycine transporter GlyT1. It is a glycine derivative.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The compound itself may have weak or undetermined in vitro activity. The methoxycarbonylamino group is a carbamate, which can be a pharmacophore for serine hydrolase inhibitors. However, no specific IC50 or EC50 data are publicly available for this compound as an inhibitor of any enzyme. In cell-based assays, it has no reported activity. |
| ln Vivo |
No in vivo activity data are available. The compound has not been administered to animals for efficacy assessment. Antibiotics or other drugs synthesized using this building block may be evaluated in animal models of infection (e.g., mice infected with S. aureus, treated with the test compound at 10-100 mg/kg IV or PO). No data exist for the building block.
|
| Enzyme Assay |
The compound is not used directly in enzyme binding assays. For chemical characterization: HPLC with a C18 column and UV detection at 210-254 nm; mobile phase water/acetonitrile (0.1% TFA). Chiral HPLC on a Chiralpak column confirms enantiomeric purity (>99%). NMR in DMSO-d₆: methoxy group (3.6 ppm), aromatic protons (7.3-7.5 ppm), carbamate NH (~8.0-8.5 ppm). Solubility: DMSO, methanol; low water solubility. No biological assays.
|
| Cell Assay |
No cell-based protocols are established for this building block. For beta-lactam antibiotics derived from D-phenylglycine, typical cell-based assays include: minimum inhibitory concentration (MIC) determination using a broth microdilution method in 96-well plates. Serial dilutions of the antibiotic (0.125-128 ug/mL) are added to bacterial cultures (10⁵ CFU/mL) and incubated at 37degC for 18-24 hours. MIC is the lowest concentration with no visible growth. The building block is not used.
|
| Animal Protocol |
No animal studies have been conducted with this building block. For ampicillin and related drugs, typical in vivo efficacy studies: mice (ICR, 6 weeks) are infected intraperitoneally with a lethal dose of E. coli or S. aureus. Test compound (e.g., 10-100 mg/kg) is administered orally or subcutaneously 1 hour post-infection. Survival is monitored for 7 days. Bacterial load in blood is measured by CFU plating. No data for the building block.
|
| ADME/Pharmacokinetics |
No PK data are available for (R)-2-((Methoxycarbonyl)amino)-2-phenylacetic acid. It is not a drug candidate. The methoxycarbonyl group is likely cleaved by esterases or carbamoylases. The free amino group (D-phenylglycine) might be absorbed and excreted unchanged or metabolized. Ampicillin (which contains a D-phenylglycine moiety without the MOC group) has low oral bioavailability (30-50%) and a half-life of 1 hour in humans. No ADME data for the MOC derivative.
|
| Toxicity/Toxicokinetics |
Safety: May cause skin and eye irritation. Harmful if swallowed (estimated LD50 >2000 mg/kg). Not classified as carcinogen or mutagen based on structural alerts. Use standard PPE: gloves, lab coat, safety goggles, fume hood. Avoid inhalation of dust. Stable as a powder at -20degC.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
(R)-2-((Methoxycarbonyl)amino)-2-phenylacetic acid is not an approved drug and has no clinical trial history. It is a research chemical for peptide synthesis and medicinal chemistry. D-Phenylglycine is a key component of semisynthetic penicillins (e.g., ampicillin, amoxicillin) and cephalosporins (e.g., cephalexin). The methoxycarbonyl (MOC) protecting group is often used in peptide synthesis as a mild, base-labile carbamate. This compound is also known as MOC-D-Phg-OH and is used to introduce a D-phenylglycine residue with an N-terminal MOC group that can be selectively deprotected. This versatility makes it valuable for constructing peptide beta-lactam antibiotics, protease inhibitors, and other bioactive molecules. Commercially available for research use only.
|
| Molecular Formula |
C10H11NO4
|
|---|---|
| Molecular Weight |
209.20
|
| Exact Mass |
209.068
|
| CAS # |
50890-96-5
|
| PubChem CID |
10910775
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
391.3±35.0 °C at 760 mmHg
|
| Melting Point |
120 °C
|
| Flash Point |
190.5±25.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
1.52
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
236
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])C([C@@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(=O)OC([H])([H])[H])=O
|
| InChi Key |
GOJLQSAREKTKPT-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C10H11NO4/c1-15-10(14)11-8(9(12)13)7-5-3-2-4-6-7/h2-6,8H,1H3,(H,11,14)(H,12,13)/t8-/m1/s1
|
| Chemical Name |
(2R)-2-(methoxycarbonylamino)-2-phenylacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7801 mL | 23.9006 mL | 47.8011 mL | |
| 5 mM | 0.9560 mL | 4.7801 mL | 9.5602 mL | |
| 10 mM | 0.4780 mL | 2.3901 mL | 4.7801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
